|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson KC: The 39th David A. Karnofsky
Lecture: Bench-to-bedside translation of targeted therapies in
multiple myeloma. J Clin Oncol. 30:445–452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang WC and Lin SF: Mechanisms of drug
resistance in relapse and refractory multiple myeloma. BioMed Res
Int. 2015:3414302015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Lee JH, Lahuerta JJ, Morgan G,
Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, et al: International Myeloma Working Group: Risk of progression
and survival in multiple myeloma relapsing after therapy with IMiDs
and bortezomib: A multicenter international myeloma working group
study. Leukemia. 26:149–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta SC, Kannappan R, Reuter S, Kim JH
and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann
NY Acad Sci. 1215:150–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhardwaj A, Sethi G, Vadhan-Raj S,
Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal
BB: Resveratrol inhibits proliferation, induces apoptosis, and
overcomes chemoresistance through down-regulation of STAT3 and
nuclear factor-kappaB-regulated antiapoptotic and cell survival
gene products in human multiple myeloma cells. Blood.
109:2293–2302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu Y, He W, Gao X, Li B, Mei C, Xu R and
Chen H: Resveratrol overcomes gefitinib resistance by increasing
the intracellular gefitinib concentration and triggering apoptosis,
autophagy and senescence in PC9/G NSCLC cells. Sci Rep.
5:177302015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato A, Naiki-Ito A, Nakazawa T, Hayashi
K, Naitoh I, Miyabe K, Shimizu S, Kondo H, Nishi Y, Yoshida M, et
al: Chemopreventive effect of resveratrol and apocynin on
pancreatic carcinogenesis via modulation of nuclear phosphorylated
GSK3β and ERK1/2. Oncotarget. 6:42963–42975. 2015.PubMed/NCBI
|
|
9
|
Yaseen A, Chen S, Hock S, Rosato R, Dent
P, Dai Y and Grant S: Resveratrol sensitizes acute myelogenous
leukemia cells to histone deacetylase inhibitors through reactive
oxygen species-mediated activation of the extrinsic apoptotic
pathway. Mol Pharmacol. 82:1030–1041. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Estrela JM, Ortega A, Mena S, Rodriguez ML
and Asensi M: Pterostilbene: Biomedical applications. Crit Rev Clin
Lab Sci. 50:65–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McCormack D and McFadden D: Pterostilbene
and cancer: Current review. J Surg Res. 173:e53–e61. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen RJ, Ho CT and Wang YJ: Pterostilbene
induces autophagy and apoptosis in sensitive and chemoresistant
human bladder cancer cells. Mol Nutr Food Res. 54:1819–1832. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tolomeo M, Grimaudo S, Di Cristina A,
Roberti M, Pizzirani D, Meli M, Dusonchet L, Gebbia N, Abbadessa V,
Crosta L, et al: Pterostilbene and 3′-hydroxypterostilbene are
effective apoptosis-inducing agents in MDR and BCR-ABL-expressing
leukemia cells. Int J Biochem Cell Biol. 37:1709–1726. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hollville E and Martin SJ: Measuring
apoptosis by microscopy and flow cytometry. Curr Protoc Immunol.
112:1–24. 2016.
|
|
15
|
Koff JL, Ramachandiran S and
Bernal-Mizrachi L: A time to kill: Targeting apoptosis in cancer.
Int J Mol Sci. 16:2942–2955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Mol Cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan T-J, Han L-H, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu R, Xi H, Li YH, Jiang H, Zou JF and
Hou J: Establishment of a bortezomib-resistant myeloma cell line
and differential proteins analysis by MALDI-OF-MS. Zhejiang Da Xue
Xue Bao Yi Xue Ban. 38:445–452. 2009.(In Chinese). PubMed/NCBI
|
|
19
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan
JA, Tammareddi A, Moore VG, Deng J, Anderson KC, Richardson P, Tai
YT, et al: Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science.
334:1129–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsiao PC, Chou YE, Tan P, Lee WJ, Yang SF,
Chow JM, Chen HY, Lin CH, Lee LM and Chien MH: Pterostilbene
simultaneously induced G0/G1-phase arrest and MAPK-mediated
mitochondrial-derived apoptosis in human acute myeloid leukemia
cell lines. PLoS One. 9:e1053422014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu W, Chen Y, Xiang R, Xu W, Wang Y, Tong
J, Zhang N, Wu Y and Yan H: Novel phosphatidylinositol 3-kinase
inhibitor BKM120 enhances the sensitivity of multiple myeloma to
bortezomib and overcomes resistance. Leuk Lymphoma. 58:428–437.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonner WM, Redon CE, Dickey JS, Nakamura
AJ, Sedelnikova OA, Solier S and Pommier Y: GammaH2AX and cancer.
Nat Rev Cancer. 8:957–967. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Murray MY, Auger MJ and Bowles KM:
Overcoming bortezomib resistance in multiple myeloma. Biochem Soc
Trans. 42:804–808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reis-Sobreiro M, Gajate C and Mollinedo F:
Involvement of mitochondria and recruitment of Fas/CD95 signaling
in lipid rafts in resveratrol-mediated antimyeloma and antileukemia
actions. Oncogene. 28:3221–3234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hsieh MJ, Lin CW, Yang SF, Sheu GT, Yu YY,
Chen MK and Chiou HL: A combination of pterostilbene with autophagy
inhibitors exerts efficient apoptotic characteristics in both
chemosensitive and chemoresistant lung cancer cells. Toxicol Sci.
137:65–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang Y, Yan X, Duan W, Yan J, Yi W, Liang
Z, Wang N, Li Y, Chen W, Yu S, et al: Pterostilbene exerts
antitumor activity via the Notch1 signaling pathway in human lung
adenocarcinoma cells. PLoS One. 8:e626522013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schneider JG, Alosi JA, McDonald DE and
McFadden DW: Effects of pterostilbene on melanoma alone and in
synergy with inositol hexaphosphate. Am J Surg. 198:679–684. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ikeda H, Hideshima T, Fulciniti M, Perrone
G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, et
al: PI3K/p110{delta} is a novel therapeutic target in multiple
myeloma. Blood. 116:1460–1468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shao X, Lai D, Zhang L and Xu H: Induction
of autophagy and apoptosis via PI3K/AKT/TOR pathways by
azadirachtin A in Spodoptera litura cells. Sci Rep. 6:354822016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wahl DR and Lawrence TS: Integrating
chemoradiation and molecularly targeted therapy. Adv Drug Deliv
Rev. 109:74–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Golubnitschaja O: Cell cycle checkpoints:
The role and evaluation for early diagnosis of senescence,
cardiovascular, cancer, and neurodegenerative diseases. Amino
Acids. 32:359–371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Walworth NC: Cell-cycle checkpoint
kinases: Checking in on the cell cycle. Curr Opin Cell Biol.
12:697–704. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pietenpol JA and Stewart ZA: Cell cycle
checkpoint signaling: Cell cycle arrest versus apoptosis.
Toxicology 181–182. 475–481. 2002. View Article : Google Scholar
|
|
37
|
Raedler LA: Farydak (panobinostat): First
HDAC inhibitor approved for patients with relapsed multiple
myeloma. Am Health Drug Benefits. 9:84–87. 2016.PubMed/NCBI
|
|
38
|
Corrales-Medina FF, Manton CA, Orlowski RZ
and Chandra J: Efficacy of panobinostat and marizomib in acute
myeloid leukemia and bortezomib-resistant models. Leuk Res.
39:371–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maiso P, Carvajal-Vergara X, Ocio EM,
López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A and San
Miguel JF: The histone deacetylase inhibitor LBH589 is a potent
antimyeloma agent that overcomes drug resistance. Cancer Res.
66:5781–5789. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Afifi S, Michael A, Azimi M, Rodriguez M,
Lendvai N and Landgren O: Role of histone deacetylase inhibitors in
relapsed refractory multiple myeloma: A focus on vorinostat and
panobinostat. Pharmacotherapy. 35:1173–1188. 2015. View Article : Google Scholar : PubMed/NCBI
|
